Contemporary personalized β-blocker management in the perioperative setting

  • Adriana D. Oprea
  • Xiaoxiao Wang
  • Robert Sickeler
  • Miklos D. KertaiEmail author
Review Article


Beta-adrenergic blockers (β-blockers) are clearly indicated for the long-term treatment of patients with systolic heart failure and post-acute myocardial infarction. Early small-scale studies reported their potential benefits for perioperative use; subsequent randomized controlled trials, however, failed to reproduce earlier findings. Furthermore, their role in reducing major postoperative cardiac events following noncardiac and cardiac surgery remains controversial. This case-based review presents an overview of contemporary literature on perioperative β-blocker use with a focus on data available since 2008 when the PreOperative ISchemic Evaluation (POISE) trial was published. Our review suggests that studies should determine the effects of situational-based guidelines on perioperative β-blocker use on the risk of cardiac adverse events and mortality in the perioperative period.


β-Blockers Cardiac surgery Noncardiac surgery Outcomes 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Mushtaq M, Cohn SL. Perioperative beta-blockers in noncardiac surgery: the evidence continues to evolve. Cleve Clin J Med. 2014;81:501–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Frishman WH. β-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013;18:310–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth. 2002;88:101–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Landesberg G. The pathophysiology of perioperative myocardial infarction: facts and perspectives. J Cardiothorac Vasc Anesth. 2003;17:90–100.PubMedCrossRefGoogle Scholar
  5. 5.
    Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839–47.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Karam D, Arora R. Perioperative β-blockers in patients undergoing noncardiac surgery-scientific misconduct and clinical guidelines. Am J Ther. 2017;24:e435–e441441.PubMedCrossRefGoogle Scholar
  7. 7.
    Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77–137.PubMedCrossRefGoogle Scholar
  8. 8.
    Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F–32F2F.PubMedCrossRefGoogle Scholar
  9. 9.
    Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ. 2005;331:932.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative β-blockade and postoperative mortality. Anesthesiology. 2010;113:794–805.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Kwon S, Thompson R, Florence M, Maier R, McIntyre L, Rogers T, Farrohki E, Whiteford M, Flum DR. β-blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. Arch Surg. 2012;147:467–73.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Bemenderfer TB, Rozario NL, Moore CG, Karunakar MA. Morbidity and mortality in elective total hip arthroplasty following surgical care improvement project guidelines. J Arthroplasty. 2017;32:2359–62.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Kertai MD, Cooter M, Pollard RJ, Buhrman W, Aronson S, Mathew JP, Stafford-Smith M. Is compliance with surgical care improvement project cardiac (SCIP-Card-2) measures for perioperative β-blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery? Anesth Analg. 2018;126:1829–38.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Khanna AK, Naylor DF, Naylor AJ, Mascha EJ, You J, Reville EM, Riter QM, Diwan M, Kurz A, Sessler DI. Early resumption of β-blockers is associated withdecreased atrial fibrillation after noncardiothoracic and nonvascular surgery: a cohort analysis. Anesthesiology. 2018;129:1101–10.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative beta-blockade: results of the metoprolol after vascular surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006;152:983–90.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Nørgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen MB, Jørgensen L, Jørgensen J, Rovsing ML, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Mølgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D, Munksgaard A, Madsen JB, Øberg B, Khanykin B, Blemmer T, Yndgaard S, Perko G, Wang LP, Winkel P, Hilden J, Jensen P, Salas N. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ. 2006;332:1482.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR, POBBLE trial investigators. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg. 2005;41:602–9.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Jacka MJ, Guyatt G, Mizera R, Vlymen J, Leon DP, Schricker T, Bahari MY, Lv B, Afzal L, García MP, Wu X, Maia LN, Arrieta M, Rao-Melacini P, Devereaux PJ. Age does mot affect metoprolol's effect on perioperative outcomes (from the POISE database). Anesth Analg. 2018;126:1150–7.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372:1962–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Flu WJ, van Kuijk JP, Chonchol M, Winkel TA, Verhagen HJ, Bax JJ, Poldermans D. Timing of pre-operative Beta-blocker treatment in vascular surgery patients: influence on post-operative outcome. J Am Coll Cardiol. 2010;56:1922–9.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Talati R, Reinhart KM, White CM, Phung OJ, Sedrakyan A, Kluger J, Coleman CI. Outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery: a meta-analysis. Ann Pharmacother. 2009;43:1181–8.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart. 2014;100:456–64.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chen RJ, Chu H, Tsai LW. Impact of beta-blocker initiation timing on mortality risk in patients with diabetes mellitus undergoing noncardiac surgery: a nationwide population-based cohort study. J Am Heart Assoc. 2017;6:e004392.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis. Br J Anaesth. 2017;118:11–21.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043–9.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014;174:336–44.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013;309:1704–13.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Friedell ML, Van Way CW, Freyberg RW, Almenoff PL. β-Blockade and operative mortality in noncardiac surgery: harmful or helpful? JAMA Surg. 2015;150:658–63.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Park J, Kim J, Kwon JH, Park SJ, Min JJ, Lee SM, Gwon HC, Lee YT, Park M, Lee SH. Association between perioperative β-blocker use and clinical outcome of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure. PLoS ONE. 2018;13:e0201311.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Jørgensen ME, Hlatky MA, Køber L, Sanders RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. β-blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med. 2015;175:1923–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Wijeysundera DN, Duncan D, Nkonde-Price C, Virani SS, Washam JB, Fleischmann KE, Fleisher LA. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:2406–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Wijeysundera DN, Beattie WS, Wijeysundera HC, Yun L, Austin PC, Ko DT. Duration of preoperative β-blockade and outcomes after major elective noncardiac surgery. Can J Cardiol. 2014;30:217–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Ellenberger C, Tait G, Beattie WS. Chronic β blockade is associated with a better outcome after elective noncardiac surgery than acute β blockade: a single-center propensity-matched cohort study. Anesthesiology. 2011;114:817–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Biccard BM, Sear JW, Foëx P. Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes. Br J Anaesth. 2008;100:23–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, Ford I, Gonzalez Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Luescher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Uva MS, Voudris V, Funck-Brentano C. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31:517–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Poldermans D, Boersma E, Bax JJ, Thomson IR, Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341:1789–94.PubMedCrossRefGoogle Scholar
  37. 37.
    Badgett RG, Lawrence VA, Cohn SL. Variations in pharmacology of beta-blockers may contribute to heterogeneous results in trials of perioperative beta-blockade. Anesthesiology. 2010;113:585–92.PubMedGoogle Scholar
  38. 38.
    Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335:1713–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology. 2011;114:824–36.PubMedCrossRefGoogle Scholar
  40. 40.
    Mashour GA, Sharifpour M, Freundlich RE, Tremper KK, Shanks A, Nallamothu BK, Vlisides PE, Weightman A, Matlen L, Merte J, Kheterpal S. Perioperative metoprolol and risk of stroke after noncardiac surgery. Anesthesiology. 2013;119:1340–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, Beattie WS. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology. 2013;119:777–87.PubMedCrossRefGoogle Scholar
  42. 42.
    Jørgensen ME, Sanders RD, Køber L, Mehta K, Torp-Pedersen C, Hlatky MA, Shaw RE, Gislason GH, Jensen PF, Andersson C. Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: a nationwide cohort study. Eur Heart J. 2017;38:2421–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Durham J, Mackey WC. Perioperative β-blockade in noncardiac surgery: a cautionary tale of over-reliance on small randomized prospective trials. Clin Ther. 2016;38:2302–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Anesth Analg. 2008;106:1039–48.PubMedCrossRefGoogle Scholar
  45. 45.
    Ollila A, Vikatmaa L, Sund R, Pettilä V, Wilkman E. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis. Ann Med. 2019;51(1):17–27.PubMedCrossRefGoogle Scholar
  46. 46.
    Landoni G, Turi S, Biondi-Zoccai G, Bignami E, Testa V, Belloni I, Hare GM. Esmolol reduces perioperative ischemia in noncardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2010;24:219–29.PubMedCrossRefGoogle Scholar
  47. 47.
    Poveda-Jaramillo R, Monaco F, Zangrillo A, Landoni G. Ultra-short-acting β-blockers (esmolol and landiolol) in the perioperative period and in critically ill patients. J Cardiothorac Vasc Anesth. 2018;32:1415–25.PubMedCrossRefGoogle Scholar
  48. 48.
    Oprea AD. Do we need another short-acting beta-blocker? A definite maybe…. J Clin Anesth. 2017;39:96–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Kato T, Kitadani J, Tabata H, Takeuchi A, Yamaue H. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017;104:1003–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Okita T, Uji M, Shinjo T, Morioka M, Kumano H, Ishimura N, Nishiwada M. Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection. Masui (Jpn J Anesthesiol). 2008;57:953–8 (in Japanese with English abstract).Google Scholar
  51. 51.
    Nakagawa H, Nanba M, Okayama Y. Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy. Masui (Jpn J Anesthesiol). 2007;56:582–5 (in Japanese with English abstract).Google Scholar
  52. 52.
    Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G, Mitsakakis N, Hare GM. Acute surgical anemia influences the cardioprotective effects of beta-blockade: a single-center, propensity-matched cohort study. Anesthesiology. 2010;112:25–33.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Brinkman W, Herbert MA, O’Brien S, Filardo G, Prince S, Dewey T, Magee M, Ryan W, Mack M. Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis. JAMA Intern Med. 2014;174:1320–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Ferguson TB Jr, Coombs LP, Peterson ED. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 2002;287:2221–7.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, DiSesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2610–42.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Brinkman WT, Herbert MA, Prince SL, Magee MJ, Dewey TM, Smith RL, Edgerton JR, Head SJ, Ryan WH, Mack MJ. Preoperative beta-blocker usage: is it really worthy of being a quality indicator? Ann Thorac Surg. 2011;92:788–96.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    LaPar DJ, Crosby IK, Kron IL, Kern JA, Fonner E, Rich JB, Speir AM, Ailawadi G. Preoperative beta-blocker use should not be a quality metric for coronary artery bypass grafting. Ann Thorac Surg. 2013;96:1539–44.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    O'Neal JB, Billings FT, Liu X, Shotwell MS, Liang Y, Shah AS, Ehrenfeld JM, Wanderer JP, Shaw AD. Effect of preoperative beta-blocker use on outcomes following cardiac surgery. Am J Cardiol. 2017;120:1293–7.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Wang L, Wang H, Hou X. Short-term effects of preoperative beta-blocker use for isolated coronary artery bypass grafting: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2018;155(620–9):e1.Google Scholar
  60. 60.
    Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, Schillinger M, Wiesbauer F, Steinwender C. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2018;3:CD004476.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Kertai MD, Esper SA, Akushevich I, Voora D, Ginsburg GS, Stafford-Smith M, Stafford-Smith M, Grichnik K, Newman MF, Fontes ML, Smith P, Podgoreanu MV, Mathew JP. Preoperative CYP2D6 metabolism-dependent beta-blocker use and mortality after coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg. 2014;147(1368–75):e3.Google Scholar
  62. 62.
    Oprea AD, Lombard FW, Kertai MD. Perioperative β-adrenergic blockade in noncardiac and cardiac surgery: a clinical update. J Cardiothorac Vasc Anesth. 2019;33:817–32.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM. Whitlock RP. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013. Scholar
  64. 64.
    Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era. Ann Noninvasive Electrocardiol. 2013;18:58–68.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Thein PM, White K, Banker K, Lunny C, Mirzaee S, Nasis A. Preoperative use of oral beta-adrenergic blocking agents and the incidence of new-onset atrial fibrillation after cardiac surgery. A systematic review and meta-analysis. Heart Lung Circ. 2018;27:310–21.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004. Scholar
  67. 67.
    Kertai MD, Qi W, Li YJ, Lombard FW, Liu Y, Smith MP, Stafford-Smith M, Newman MF, Milano CA, Mathew JP, Podgoreanu MV. Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving beta-blockers. J Mol Cell Cardiol. 2016;92:109–15.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, Roden DM, Darbar D. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012;59:49–56.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Kertai MD, Li YW, Li YJ, Shah SH, Kraus WE, Fontes ML, Stafford-Smith M, Newman MF, Podgoreanu MV, Mathew JP. G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving beta-blockers. Circ Cardiovasc Genet. 2014;7:625–33.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    DiNicolantonio JJ, Beavers CJ, Menezes AR, Lavie CJ, O'Keefe JH, Meier P, Vorobcsuk A, Aradi D, Komócsi A, Chatterjee S, D'Ascenzo F, Gasparini M, Brugts J, Biondi-Zoccai G. Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2014;113:565–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Li L, Ai Q, Lin L, Ge P, Yang C, Zhang L. Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8:10265–73.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T, Sawa Y. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery. Heart Vessels. 2013;28:490–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Sezai A, Nakai T, Hata M, Yoshitake I, Shiono M, Kunimoto S, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144:1241–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Adv Ther. 2014;31:440–50.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Tamura T, Yatabe T, Yokoyama M. Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: a systematic review and meta-analysis. J Clin Anesth. 2017;42:1–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Muehlschlegel JD, Burrage PS, Ngai JY, Prutkin JM, Huang CC, Xu X, Chae SH, Bollen BA, Piccini JP, Schwann NM, Mahajan A, Ruel M, Body SC, Sellke FW, Mathew J, O'Brien B. Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. Anesth Analg. 2019;128:33–42.PubMedGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2019

Authors and Affiliations

  1. 1.Department of AnesthesiologyYale School of MedicineNew HavenUSA
  2. 2.Division of Cardiothoracic Anesthesiology, Department of AnesthesiologyNewYork-Presbyterian Hospital and Weill Cornell MedicineNew YorkUSA
  3. 3.Division of Cardiothoracic Anesthesiology, Department of AnesthesiologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations